Pfizer's Paxlovid combines two antiviral drugs to fight the virus that causes COVID-19. Joe Raedle/Getty Images hide caption
remdesivir remdesivir
Stories About
remdesivir
Drugmaker Gilead says remdesivir has proved effective at treating patients early in the course of the disease. Dirk Waem/Belga/AFP via Getty Images hide caption
Why remdesivir, a highly effective COVID treatment, is a last resort for providers
Boxes containing vials of remdesivir at a pharmaceutical company in Giza, Egypt. Fadel Dawood/DPA/Picture Alliance via Getty Images hide caption
In this photo provided by Eli Lilly, a researcher tests possible COVID-19 antibodies in a laboratory in Indianapolis, Ind. On Monday, U.S. government officials announced they are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalized with COVID-19 because it is unlikely to help. David Morrison/AP hide caption
Boxes of remdesivir, an antiviral drug considered a promising treatment for COVID-19. Sima Diab/Bloomberg via Getty Images hide caption
Dr. Sean Dooley briefs reporters at Walter Reed National Military Medical Center in Bethesda, Md. on Saturday. Trump was admitted to the hospital after contracting the coronavirus. Susan Walsh/AP hide caption
Niticia Mpanga, a registered respiratory therapist, checks on an ICU patient at Oakbend Medical Center in Richmond, Texas. The mortality rates from COVID-19 in ICUs have been decreasing worldwide, doctors say, at least partly because of recent advances in treatment. Mark Felix/AFP via Getty Images hide caption
Advances In ICU Care Are Saving More Patients Who Have COVID-19
The experimental antiviral drug remdesivir shortened hospital stays for seriously ill COVID-19 patients in a federally funded study. But there's not enough of the medicine to go around. Ulrich Perrey/Pool/AFP via Getty Images hide caption
How Feds Decide On Remdesivir Shipments To States Remains Mysterious
Gilead Sciences, maker of the antiviral drug remdesivir, has come up with a price for the COVID-19 treatment that was less than some analysts expected. ULRICH PERREY/POOL/AFP via Getty Images hide caption
Remdesivir Priced At More Than $3,100 For A Course Of Treatment
A researcher at the German Center for Immunity Therapy holds a bag containing blood plasma from a recovered COVID-19 patient at the University Hospital Erlangen on April 27, 2020 in Erlangen, Germany. This plasma could be used to treat people with COVID-19. Alexander Hassenstein/Getty Images hide caption
Five Coronavirus Treatments In Development
Stoppers are placed on filled vials of the experimental drug remdesivir at a Gilead Sciences factory. Gilead Sciences/AP hide caption
Remdesivir, an experimental antiviral drug made by Gilead Sciences, has been authorized by the Food and Drug Administration for emergency use in treating severely ill COVID-19 patients. Ulrich Perry/POOL/AFP via Getty Images hide caption
Gilead Sciences CEO Daniel O'Day speaks at a meeting with President Trump and members of the White House coronavirus task force on March 2. Andrew Harnik/AP hide caption
Preliminary results of a study of the antiviral drug remdesivir show it is effective in shortening the recovery time for patients with COVID-19. Gilead Sciences via AP hide caption
After the Food and Drug Administration granted Gilead Sciences orphan drug status for its experimental drug remdesivir on Tuesday, Gilead asked that the agency rescind that status Wednesday. Bloomberg/Bloomberg via Getty Images hide caption
Gilead Sciences CEO Daniel O'Day (center) took part in a meeting of the White House Coronavirus Task Force on March 2. Andrew Harnik/AP hide caption